RecruitingNot ApplicableNCT06515210

Personalized Anti-Inflammatory Fibres in Ulcerative Colitis

Clinical Profiling of Anti-inflammatory Fibre Supplements in Patients With Ulcerative Colitis: Towards Personalized Complementary Strategies.


Sponsor

University of Alberta

Enrollment

69 participants

Start Date

Jun 3, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to determine the clinical effects of two different dietary fibre supplements, acacia gum (AG) and microcrystalline cellulose (MCC), in patients with ulcerative colitis. The main question it aims to answer is: Can the fibre supplements reduce gut inflammation (fecal calprotectin)? Researchers will compare AG and MCC to a placebo (a look-alike substance that contains no fibre) to see if the fibre supplements improve inflammation in ulcerative colitis. Participants will add their assigned fibre supplement or placebo to their usual diet daily for 6 weeks. They will visit the clinic at baseline, week 3, and week 6 to provide samples (stool, blood) and complete various questionnaires.


Eligibility

Min Age: 15 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether personalized dietary fiber supplements can reduce gut inflammation and improve symptoms in people with mild ulcerative colitis (UC), a type of inflammatory bowel disease. Each participant will receive a fiber blend tailored to their own gut microbiome. **You may be eligible if...** - You have a confirmed diagnosis of ulcerative colitis - You have a fecal calprotectin (a stool inflammation marker) above 250 - Your disease is currently mild (based on standard scoring systems) - You have been on stable IBD medications for at least 3 months - You weigh more than 50 kg - Pediatric patients: must be at Tanner stage 5 and have mild disease on pediatric scoring - Women: must be menstruating and using contraceptives **You may NOT be eligible if...** - You have Crohn's disease, indeterminate colitis, celiac disease, or a motility disorder - You have taken antibiotics for more than a week in the 2 months before the study - You are unable to give informed consent - Your IBD medications were recently changed Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTAcacia Gum

Participants (n=23) incorporate the fibre supplement into their usual diet daily.

DIETARY_SUPPLEMENTMicrocrystalline Cellulose

Participants (n=23) incorporate the fibre supplement into their usual diet daily.

DIETARY_SUPPLEMENTPlacebo

Participants (n=23) incorporate the placebo into their usual diet daily.


Locations(1)

University of Alberta Hospital

Edmonton, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06515210


Related Trials